Introduction: Available clinical data on the influence of baseline HbA postoperative morbidity and readmission after laparoscopic sleeve gastrectomy is scarce. This prompted us to conduct a multicenter retrospective study evaluating the influence of chronic hyperglycemia on postoperative course among patients undergoing laparoscopic sleeve gastrectomy (SG). We aimed to investigate the influence of baseline HbA levels on postoperative outcomes in patients after SG.
Material And Methods: We conducted a multicenter retrospective cohort study of consecutive patients who underwent SG from March 2017 to March 2018 in seven referral centers for bariatric surgery. Exclusion criteria were revision surgeries, different bariatric interventions, SG combined with other procedures, and lack of necessary data. Patients were divided into three groups depending on their preoperative glycated hemoglobin level (HbA) < 5.7%, 5.7-6.4%, and ≥ 6.5%. Primary endpoints were influence of HbA on early and late postoperative morbidity, impact on prolonged length of hospital stay (LOS), and readmission rate.
Results: The HbA < 5.7% group comprised 842 (49%) patients, HbA 5.7-6.4% comprised 587 (34%), and HbA ≥ 6.5% comprised 289 (17%). Overall morbidity was 6.23%; this did not differ among groups (p = 0.571). Three patients died postoperatively. Late postoperative morbidity was comparable among groups (p = 0.312). The ratio of prolonged LOS and readmission did not differ among groups (p = 0.363 and 0.571). ROC analysis revealed that HbA > 7.3% increased OR for hospital readmission (p = 0.007).
Conclusion: Preoperative HbA does not affect postoperative morbidity and prolonged LOS after SG. Patients with HbA > 7.3% have an increased chance of hospital readmission.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11695-019-03936-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Semaglutide and laparoscopic sleeve gastrectomy in an adolescent with congenital adrenal hyperplasia due to 21-hydroxylase: a case report.
J Med Case Rep
January 2025
Department of Surgery, Center for Endocrinology, Diabetes and Metabolism, Children's Hospital Los Angeles and Keck School of Medicine of USC, Los Angeles, CA, USA.
Background: Classic congenital adrenal hyperplasia, primarily due to 21-hydroxylase deficiency, leads to impaired cortisol and aldosterone production and excess adrenal androgens. Lifelong glucocorticoid therapy is required, often necessitating supraphysiological doses in youth to manage androgen excess and growth acceleration. These patients experience higher obesity rates, hypertension, and glucose metabolism issues, complicating long-term health management.
View Article and Find Full Text PDFOutcomes of Metabolic and Bariatric Surgery in Patients with Inflammatory Bowel Disease: A Long-Term Retrospective Analysis.
J Clin Med
January 2025
Division of General Surgery, Tel Aviv Sourasky Medical Center, 6 Weizman St., Tel Aviv 6423906, Israel.
: Metabolic and bariatric surgery (MBS) is a well-established treatment for severe obesity, yet its effects in patients with inflammatory bowel disease (IBD) are not well understood. MBS in this population presents unique challenges, including the potential for exacerbating inflammatory disease activity and causing complications such as malnutrition and medication malabsorption. This study aims to assess the long-term outcomes of MBS in IBD patients, focusing on both metabolic outcomes and its impact on the course of IBD.
View Article and Find Full Text PDFIntegrated Insights into Metabolic and Bariatric Surgery: Improving Life Quality and Reducing Mortality in Obesity.
Medicina (Kaunas)
December 2024
Department of Medical Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, 410073 Oradea, Romania.
Metabolic and bariatric surgery (MBS) is an effective intervention for patients with severe obesity and metabolic comorbidities, particularly when non-surgical weight loss methods prove insufficient. MBS has shown significant potential for improving quality of life and metabolic health outcomes in individuals with obesity, yet it carries inherent risks. Although these procedures offer a multifaceted approach to obesity treatment and its clinical advantages are well-documented, the limited understanding of its long-term outcomes and the role of multidisciplinary care pose challenges.
View Article and Find Full Text PDF[Surgical treatment for obesity - metabolic surgery].
Orthopadie (Heidelb)
January 2025
Klinikum Dortmund, Klinik für Chirurgie, Klinikum der Universität Witten/Herdecke, Beurhausstraße 40, 44137, Dortmund, Deutschland.
Background: Over the past 20 years, surgical treatment of obesity, or metabolic surgery, has established itself as an extremely efficient and sustainable therapy for treating severely overweight patients. Compared to non-surgical weight reduction procedures, surgical techniques have been shown to be superior in all studies, both in terms of short-term and long-term effectiveness. On the other hand, the invasiveness of the procedures is something that many patients view critically.
View Article and Find Full Text PDFMitochondrial oxygen metabolism as a potential predictor of weight loss after laparoscopic sleeve gastrectomy for class III obesity.
Front Endocrinol (Lausanne)
January 2025
Department of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Friedrich-Schiller-University Jena, Jena, Germany.
Unlabelled: The prevalence of obesity is increasing at an alarming rate in industrialized countries. Obesity is a systemic disease that causes not only macroscopic alterations, but also mitochondrial dysfunction. Laparoscopic sleeve gastrectomy (LSG) poses a potential therapeutic option for patients with severe obesity.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!